PL2925735T3 - Inhibitory kotransportera sodowo-glukozowego 1 - Google Patents

Inhibitory kotransportera sodowo-glukozowego 1

Info

Publication number: PL2925735T3
Authority: PL; Poland
Prior art keywords: inhibitors; glucose cotransporter; sodium glucose; sodium; cotransporter
Prior art date: 2012-11-20

Application number

PL13802774T

Other languages

English (en)

Inventor

Kenneth Gordon Carson

Nicole Cathleen Goodwin

Bryce Alden Harrison

David Brent Rawlins

Eric Strobel

Brian Zambrowicz

Original Assignee

Lexicon Pharmaceuticals, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-11-20

Filing date

2013-11-18

Publication date

2019-08-30

2013-11-18 Application filed by Lexicon Pharmaceuticals, Inc. filed Critical Lexicon Pharmaceuticals, Inc.

2019-08-30 Publication of PL2925735T3 publication Critical patent/PL2925735T3/pl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/14—Acyclic radicals, not substituted by cyclic structures attached to a sulfur, selenium or tellurium atom of a saccharide radical
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Genetics & Genomics (AREA)
Obesity (AREA)
Cardiology (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Crystallography & Structural Chemistry (AREA)
Urology & Nephrology (AREA)
Child & Adolescent Psychology (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Epidemiology (AREA)
Saccharide Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PL13802774T 2012-11-20 2013-11-18 Inhibitory kotransportera sodowo-glukozowego 1 PL2925735T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201261728373P	2012-11-20	2012-11-20
PCT/US2013/070556 WO2014081660A1 (en)	2012-11-20	2013-11-18	Inhibitors of sodium glucose cotransporter 1
EP13802774.3A EP2925735B1 (en)	2012-11-20	2013-11-18	Inhibitors of sodium glucose cotransporter 1

Publications (1)

Publication Number	Publication Date
PL2925735T3 true PL2925735T3 (pl)	2019-08-30

Family

ID=49753472

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL13802774T PL2925735T3 (pl)	2012-11-20	2013-11-18	Inhibitory kotransportera sodowo-glukozowego 1
PL18213751T PL3489226T3 (pl)	2012-11-20	2013-11-18	Inhibitory kotransportera glukozowo-sodowego 1

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PL18213751T PL3489226T3 (pl)	2012-11-20	2013-11-18	Inhibitory kotransportera glukozowo-sodowego 1

Country Status (25)

Country	Link
US (3)	US9200025B2 (pl)
EP (2)	EP3489226B1 (pl)
JP (1)	JP6278971B2 (pl)
KR (1)	KR102165224B1 (pl)
CN (1)	CN108440614A (pl)
AR (1)	AR093572A1 (pl)
AU (1)	AU2013348233C1 (pl)
BR (1)	BR112015011298B1 (pl)
CA (1)	CA2891773C (pl)
DK (2)	DK2925735T3 (pl)
ES (2)	ES2728246T3 (pl)
HK (2)	HK1208458A1 (pl)
HU (2)	HUE054063T2 (pl)
IL (1)	IL238590B (pl)
MX (1)	MX365753B (pl)
NZ (1)	NZ707859A (pl)
PL (2)	PL2925735T3 (pl)
PT (2)	PT3489226T (pl)
RU (1)	RU2015123738A (pl)
SG (1)	SG11201503923XA (pl)
TR (1)	TR201908247T4 (pl)
TW (1)	TWI636058B (pl)
UA (1)	UA117574C2 (pl)
WO (1)	WO2014081660A1 (pl)
ZA (1)	ZA201503331B (pl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI499414B (zh) *	2006-09-29	2015-09-11	Lexicon Pharmaceuticals Inc	鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ２）的抑制物與其應用方法
PL2925735T3 (pl)	2012-11-20	2019-08-30	Lexicon Pharmaceuticals, Inc.	Inhibitory kotransportera sodowo-glukozowego 1
AU2014213251B2 (en)	2013-02-04	2017-07-20	Taisho Pharmaceutical Co., Ltd.	Prophylactic or therapeutic drug for constipation
CN104478671B (zh) *	2015-01-15	2016-03-09	佛山市赛维斯医药科技有限公司	一类双烷氧苯基丙二醇衍生物和用途
CN104478674B (zh) *	2015-01-15	2016-03-09	佛山市赛维斯医药科技有限公司	一类烷氧苯基丙二醇衍生物和用途
CN104478675B (zh) *	2015-01-15	2016-01-06	佛山市赛维斯医药科技有限公司	一类含烷氧苯基和三氟甲苯基丙二醇结构的衍生物和用途
CN107540685B (zh) *	2017-09-04	2020-05-05	杭州科巢生物科技有限公司	一种Sotagliflozin的制备方法及其中间体
CN110066302B (zh) *	2018-01-23	2022-12-27	广东东阳光药业有限公司	吡喃葡萄糖基衍生物及其用途
EP3747892A4 (en) *	2018-01-31	2021-11-03	Sunshine Lake Pharma Co., Ltd.	GLUCOPYRANOSYL DERIVATIVE AND USE OF IT
CN112469407B (zh)	2018-03-28	2024-10-01	阿沃林特有限公司	用于治疗餐后低血糖症的方法
CA3113037A1 (en) *	2018-09-26	2020-04-02	Lexicon Pharmaceuticals, Inc.	Crystalline forms of n-(1-((2-(dimethylamino)ethyl)amino)-2-methyl-1-oopropan-2-yl)-4-(4-(2-methyl-5-(2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2h-pyran-2-yl)benzyl)phenl)butanamide and methods of their synthesis
WO2020200153A1 (zh)	2019-03-29	2020-10-08	南京明德新药研发有限公司	作为sglt1抑制剂的葡糖苷类衍生物及其应用
CN112209908B (zh) *	2019-07-10	2024-04-26	东莞市东阳光新药研发有限公司	吡喃葡萄糖基衍生物及其用途
EP4005568B1 (en) *	2019-07-26	2024-07-10	Dongbao Purple Star (Hangzhou) Biopharmaceutical Co., Ltd.	Sglts/dpp4 inhibitor and application thereof
EP4006017B1 (en) *	2019-07-26	2024-10-23	CGenetech (Suzhou, China) Co., Ltd.	Sglt2/dpp4 inhibitor and application thereof
CN114423775A (zh) *	2020-05-15	2022-04-29	上海喆邺生物科技有限公司	一类芳基葡糖苷衍生物及其制备方法和应用
CN113893351A (zh) *	2020-07-06	2022-01-07	诺未科技（北京）有限公司	组合物及其在制备治疗癌症的药物中的应用
WO2022063305A1 (zh) *	2020-09-27	2022-03-31	南京明德新药研发有限公司	葡糖苷类化合物的晶型及其应用

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3674836A (en)	1968-05-21	1972-07-04	Parke Davis & Co	2,2-dimethyl-{11 -aryloxy-alkanoic acids and salts and esters thereof
US4027009A (en)	1973-06-11	1977-05-31	Merck & Co., Inc.	Compositions and methods for depressing blood serum cholesterol
JPS5612114B2 (pl)	1974-06-07	1981-03-18
US4231938A (en)	1979-06-15	1980-11-04	Merck & Co., Inc.	Hypocholesteremic fermentation products and process of preparation
DK149080C (da)	1980-06-06	1986-07-28	Sankyo Co	Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
US4450171A (en)	1980-08-05	1984-05-22	Merck & Co., Inc.	Antihypercholesterolemic compounds
US4448784A (en)	1982-04-12	1984-05-15	Hoechst-Roussel Pharmaceuticals, Inc.	1-(Aminoalkylphenyl and aminoalkylbenzyl)-indoles and indolines and analgesic method of use thereof
US5354772A (en)	1982-11-22	1994-10-11	Sandoz Pharm. Corp.	Indole analogs of mevalonolactone and derivatives thereof
US4499289A (en)	1982-12-03	1985-02-12	G. D. Searle & Co.	Octahydronapthalenes
CA1327360C (en)	1983-11-14	1994-03-01	William F. Hoffman	Oxo-analogs of mevinolin-like antihypercholesterolemic agents
US4613610A (en)	1984-06-22	1986-09-23	Sandoz Pharmaceuticals Corp.	Cholesterol biosynthesis inhibiting pyrazole analogs of mevalonolactone and its derivatives
US4686237A (en)	1984-07-24	1987-08-11	Sandoz Pharmaceuticals Corp.	Erythro-(E)-7-[3'-C1-3 alkyl-1'-(3",5"-dimethylphenyl)naphth-2'-yl]-3,5-dihydroxyhept-6-enoic acids and derivatives thereof
US4647576A (en)	1984-09-24	1987-03-03	Warner-Lambert Company	Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis
ATE60571T1 (de)	1984-12-04	1991-02-15	Sandoz Ag	Inden-analoga von mevalonolakton und ihre derivate.
US4668794A (en)	1985-05-22	1987-05-26	Sandoz Pharm. Corp.	Intermediate imidazole acrolein analogs
KR900001212B1 (ko)	1985-10-25	1990-02-28	산도즈 파마슈티칼스 코오포레이숀	메바로노락톤 및 그것의 유도체의 헤테로사이클릭 유사체 및 그것의 생산방법 및 약학적인 그것의 용도
FR2596393B1 (fr)	1986-04-01	1988-06-03	Sanofi Sa	Derives de l'acide hydroxy-3 dihydroxyoxophosphorio-4 butanoique, leur procede de preparation, leur application comme medicament et les compositions les renfermant
US5614492A (en)	1986-05-05	1997-03-25	The General Hospital Corporation	Insulinotropic hormone GLP-1 (7-36) and uses thereof
US4681893A (en)	1986-05-30	1987-07-21	Warner-Lambert Company	Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
IT1217685B (it)	1987-05-22	1990-03-30	Squibb & Sons Inc	Inibitori della hmg coa riduttasi contenenti fosforo e metodo per il loro impiego
US4759923A (en)	1987-06-25	1988-07-26	Hercules Incorporated	Process for lowering serum cholesterol using poly(diallylmethylamine) derivatives
JP2569746B2 (ja)	1987-08-20	1997-01-08	日産化学工業株式会社	キノリン系メバロノラクトン類
US4871721A (en)	1988-01-11	1989-10-03	E. R. Squibb & Sons, Inc.	Phosphorus-containing squalene synthetase inhibitors
US4924024A (en)	1988-01-11	1990-05-08	E. R. Squibb & Sons, Inc.	Phosphorus-containing squalene synthetase inhibitors, new intermediates and method
NO177005C (no)	1988-01-20	1995-07-05	Bayer Ag	Analogifremgangsmåte for fremstilling av substituerte pyridiner, samt mellomprodukter til bruk ved fremstillingen
US5506219A (en)	1988-08-29	1996-04-09	E. R. Squibb & Sons, Inc.	Pyridine anchors for HMG-CoA reductase inhibitors
US5753675A (en)	1989-03-03	1998-05-19	Novartis Pharmaceuticals Corporation	Quinoline analogs of mevalonolactone and derivatives thereof
FI94339C (fi)	1989-07-21	1995-08-25	Warner Lambert Co	Menetelmä farmaseuttisesti käyttökelpoisen /R-(R,R)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5177080A (en)	1990-12-14	1993-01-05	Bayer Aktiengesellschaft	Substituted pyridyl-dihydroxy-heptenoic acid and its salts
JP2648897B2 (ja)	1991-07-01	1997-09-03	塩野義製薬株式会社	ピリミジン誘導体
US5595872A (en)	1992-03-06	1997-01-21	Bristol-Myers Squibb Company	Nucleic acids encoding microsomal trigyceride transfer protein
US5470845A (en)	1992-10-28	1995-11-28	Bristol-Myers Squibb Company	Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia
US5594016A (en)	1992-12-28	1997-01-14	Mitsubishi Chemical Corporation	Naphthalene derivatives
WO1994016693A1 (en)	1993-01-19	1994-08-04	Warner-Lambert Company	Stable oral ci-981 formulation and process of preparing same
US5739135A (en)	1993-09-03	1998-04-14	Bristol-Myers Squibb Company	Inhibitors of microsomal triglyceride transfer protein and method
US5776983A (en)	1993-12-21	1998-07-07	Bristol-Myers Squibb Company	Catecholamine surrogates useful as β3 agonists
US5488064A (en)	1994-05-02	1996-01-30	Bristol-Myers Squibb Company	Benzo 1,3 dioxole derivatives
US5385929A (en)	1994-05-04	1995-01-31	Warner-Lambert Company	[(Hydroxyphenylamino) carbonyl] pyrroles
US5612359A (en)	1994-08-26	1997-03-18	Bristol-Myers Squibb Company	Substituted biphenyl isoxazole sulfonamides
US5491134A (en)	1994-09-16	1996-02-13	Bristol-Myers Squibb Company	Sulfonic, phosphonic or phosphiniic acid β3 agonist derivatives
US5541204A (en)	1994-12-02	1996-07-30	Bristol-Myers Squibb Company	Aryloxypropanolamine β 3 adrenergic agonists
US5620997A (en)	1995-05-31	1997-04-15	Warner-Lambert Company	Isothiazolones
AU6966696A (en)	1995-10-05	1997-04-28	Warner-Lambert Company	Method for treating and preventing inflammation and atherosclerosis
ATE344279T1 (de)	1995-12-13	2006-11-15	Univ California	Kristalle der mit einem ligand komplexierten ligandenbindedomäne des schilddrüsenhormonrezeptors
US5770615A (en)	1996-04-04	1998-06-23	Bristol-Myers Squibb Company	Catecholamine surrogates useful as β3 agonists
US5962440A (en)	1996-05-09	1999-10-05	Bristol-Myers Squibb Company	Cyclic phosphonate ester inhibitors of microsomal triglyceride transfer protein and method
US5885983A (en)	1996-05-10	1999-03-23	Bristol-Myers Squibb Company	Inhibitors of microsomal triglyceride transfer protein and method
US5827875A (en)	1996-05-10	1998-10-27	Bristol-Myers Squibb Company	Inhibitors of microsomal triglyceride transfer protein and method
US5760246A (en)	1996-12-17	1998-06-02	Biller; Scott A.	Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method
TW536540B (en)	1997-01-30	2003-06-11	Bristol Myers Squibb Co	Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
GB9713739D0 (en)	1997-06-27	1997-09-03	Karobio Ab	Thyroid receptor ligands
EP2433623A1 (en)	1998-02-02	2012-03-28	Trustees Of Tufts College	Use of dipeptidylpeptidase inhibitors to regulate glucose metabolism
JP2002506075A (ja)	1998-03-09	2002-02-26	フォンダテッヒ・ベネルクス・ナムローゼ・フェンノートシャップ	セリンペプチダーゼ調節剤
DE19823831A1 (de)	1998-05-28	1999-12-02	Probiodrug Ges Fuer Arzneim	Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
DE19828114A1 (de)	1998-06-24	2000-01-27	Probiodrug Ges Fuer Arzneim	Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
DE19828113A1 (de)	1998-06-24	2000-01-05	Probiodrug Ges Fuer Arzneim	Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
SK18822000A3 (sk)	1998-07-06	2001-12-03	Bristol-Myers Squibb Company	Bifenylsulfónamidy ako duálne antagonisty angiotenzínového a endotelínového receptora
US6548529B1 (en)	1999-04-05	2003-04-15	Bristol-Myers Squibb Company	Heterocyclic containing biphenyl aP2 inhibitors and method
US7390824B1 (en)	1999-09-07	2008-06-24	Bristol-Myers Squibb Company	Method for treating diabetes employing an aP2 inhibitor and combination
US6414002B1 (en)	1999-09-22	2002-07-02	Bristol-Myers Squibb Company	Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
TWI260321B (en)	1999-09-22	2006-08-21	Bristol Myers Squibb Co	Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
US6395767B2 (en)	2000-03-10	2002-05-28	Bristol-Myers Squibb Company	Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
KR20040054729A (ko)	2001-10-18	2004-06-25	브리스톨-마이어스 스큅 컴퍼니	인간 글루카곤-유사-펩티드-1 모방체, 및 당뇨병 및 이와관련된 증상의 치료에 있어서 이의 용도
JP2004137245A (ja)	2002-08-23	2004-05-13	Kissei Pharmaceut Co Ltd	ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
US6995183B2 (en)	2003-08-01	2006-02-07	Bristol Myers Squibb Company	Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
JP5067644B2 (ja)	2006-05-19	2012-11-07	大正製薬株式会社	Ｃ−フェニルグリシト−ル化合物
AU2007266078B2 (en) *	2006-06-29	2011-12-15	Taisho Pharmaceutical Co., Ltd.	C-phenyl 1-thioglucitol compound
TWI499414B (zh) *	2006-09-29	2015-09-11	Lexicon Pharmaceuticals Inc	鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ２）的抑制物與其應用方法
US7846945B2 (en)	2007-03-08	2010-12-07	Lexicon Pharmaceuticals, Inc.	Piperdine-based inhibitors of sodium glucose co-transporter 2 and methods of their use
CA2694029C (en) *	2007-07-26	2016-10-04	Lexicon Pharmaceuticals, Inc.	Methods and compounds useful for the preparation of sodium glucose co-transporter 2 inhibitors
US7838499B2 (en)	2007-08-23	2010-11-23	Theracos, Inc.	Benzylbenzene derivatives and methods of use
TWI472521B (zh) *	2008-07-17	2015-02-11	Lexicon Pharmaceuticals Inc	（２ｓ，３ｒ，４ｒ，５ｓ，６ｒ）－２－（４－氯－３－（４－乙氧苄基）苯基）－６－（甲硫）四氫－２ｈ－哌喃－３，４，５－三醇的固體形態與其使用方法
EP2298782A1 (en)	2009-08-26	2011-03-23	Sanofi-Aventis	Method for producing pyrazole glycoside derivatives
US20110077212A1 (en) *	2009-09-25	2011-03-31	Theracos, Inc.	Therapeutic uses of sglt2 inhibitors
CN102510867A (zh) *	2009-10-20	2012-06-20	诺瓦提斯公司	糖苷衍生物及其用途
AR079438A1 (es) *	2009-12-09	2012-01-25	Panacea Biotec Ltd	Derivados de azucar, composiciones farmaceuticas y sus usos
TWI562775B (en) *	2010-03-02	2016-12-21	Lexicon Pharmaceuticals Inc	Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
WO2012041898A1 (en) *	2010-09-29	2012-04-05	Celon Pharma Sp. Z O.O.	Combination of sglt2 inhibitor and a sugar compound for the treatment of diabetes
TWI631963B (zh) *	2011-01-05	2018-08-11	雷西肯製藥股份有限公司	包含鈉－葡萄糖共同輸送體１與２之抑制劑的組合物與應用方法
KR20140019834A (ko) *	2011-04-14	2014-02-17	노파르티스 아게	글리코시드 유도체 및 그의 용도
PL2925735T3 (pl)	2012-11-20	2019-08-30	Lexicon Pharmaceuticals, Inc.	Inhibitory kotransportera sodowo-glukozowego 1

2013
- 2013-11-18 PL PL13802774T patent/PL2925735T3/pl unknown
- 2013-11-18 PT PT182137513T patent/PT3489226T/pt unknown
- 2013-11-18 CN CN201810447529.6A patent/CN108440614A/zh active Pending
- 2013-11-18 PT PT13802774T patent/PT2925735T/pt unknown
- 2013-11-18 TR TR2019/08247T patent/TR201908247T4/tr unknown
- 2013-11-18 WO PCT/US2013/070556 patent/WO2014081660A1/en active Application Filing
- 2013-11-18 EP EP18213751.3A patent/EP3489226B1/en active Active
- 2013-11-18 UA UAA201506106A patent/UA117574C2/uk unknown
- 2013-11-18 BR BR112015011298-6A patent/BR112015011298B1/pt active IP Right Grant
- 2013-11-18 MX MX2015006124A patent/MX365753B/es active IP Right Grant
- 2013-11-18 JP JP2015542874A patent/JP6278971B2/ja active Active
- 2013-11-18 CA CA2891773A patent/CA2891773C/en active Active
- 2013-11-18 HU HUE18213751A patent/HUE054063T2/hu unknown
- 2013-11-18 US US14/082,786 patent/US9200025B2/en active Active
- 2013-11-18 AU AU2013348233A patent/AU2013348233C1/en active Active
- 2013-11-18 KR KR1020157016124A patent/KR102165224B1/ko active IP Right Grant
- 2013-11-18 RU RU2015123738A patent/RU2015123738A/ru not_active Application Discontinuation
- 2013-11-18 DK DK13802774.3T patent/DK2925735T3/da active
- 2013-11-18 DK DK18213751.3T patent/DK3489226T3/da active
- 2013-11-18 ES ES13802774T patent/ES2728246T3/es active Active
- 2013-11-18 HU HUE13802774A patent/HUE043868T2/hu unknown
- 2013-11-18 NZ NZ707859A patent/NZ707859A/en unknown
- 2013-11-18 SG SG11201503923XA patent/SG11201503923XA/en unknown
- 2013-11-18 ES ES18213751T patent/ES2869286T3/es active Active
- 2013-11-18 PL PL18213751T patent/PL3489226T3/pl unknown
- 2013-11-18 EP EP13802774.3A patent/EP2925735B1/en active Active
- 2013-11-19 TW TW102142085A patent/TWI636058B/zh active
- 2013-11-20 AR ARP130104292A patent/AR093572A1/es unknown
2015
- 2015-05-03 IL IL238590A patent/IL238590B/en active IP Right Grant
- 2015-05-13 ZA ZA2015/03331A patent/ZA201503331B/en unknown
- 2015-09-18 HK HK15109196.6A patent/HK1208458A1/xx unknown
- 2015-11-17 US US14/943,505 patent/US9688710B2/en active Active
2017
- 2017-05-22 US US15/601,175 patent/US10106569B2/en active Active
2018
- 2018-09-12 HK HK18111721.3A patent/HK1252424A1/zh unknown

Also Published As

Publication number	Publication date
ES2728246T3 (es)	2019-10-23
DK2925735T3 (da)	2019-06-17
CN104854096A (zh)	2015-08-19
MX2015006124A (es)	2015-12-01
BR112015011298B1 (pt)	2021-12-14
NZ707859A (en)	2019-03-29
KR102165224B1 (ko)	2020-10-13
US9200025B2 (en)	2015-12-01
AU2013348233A1 (en)	2015-05-28
AU2013348233C1 (en)	2018-09-06
EP2925735B1 (en)	2019-03-13
AU2013348233B2 (en)	2017-12-14
US10106569B2 (en)	2018-10-23
TR201908247T4 (tr)	2019-06-21
TW201420595A (zh)	2014-06-01
PL3489226T3 (pl)	2021-08-02
US20160326205A1 (en)	2016-11-10
ES2869286T3 (es)	2021-10-25
TWI636058B (zh)	2018-09-21
EP3489226B1 (en)	2021-02-17
HK1208458A1 (en)	2016-03-04
IL238590A0 (en)	2015-06-30
PT2925735T (pt)	2019-06-04
US20180244708A1 (en)	2018-08-30
AR093572A1 (es)	2015-06-10
SG11201503923XA (en)	2015-06-29
EP2925735A1 (en)	2015-10-07
UA117574C2 (uk)	2018-08-27
US9688710B2 (en)	2017-06-27
HUE054063T2 (hu)	2021-08-30
HUE043868T2 (hu)	2019-09-30
PT3489226T (pt)	2021-03-02
KR20150085067A (ko)	2015-07-22
DK3489226T3 (da)	2021-04-26
BR112015011298A2 (pt)	2017-07-11
CA2891773C (en)	2021-01-19
WO2014081660A1 (en)	2014-05-30
RU2015123738A (ru)	2017-01-10
JP6278971B2 (ja)	2018-02-14
US20140309178A1 (en)	2014-10-16
CA2891773A1 (en)	2014-05-30
JP2016504285A (ja)	2016-02-12
IL238590B (en)	2018-12-31
CN108440614A (zh)	2018-08-24
EP3489226A1 (en)	2019-05-29
MX365753B (es)	2019-06-12
HK1252424A1 (zh)	2019-05-24
ZA201503331B (en)	2016-11-30

Publication	Publication Date	Title
HK1252424A1 (zh)	2019-05-24	鈉葡萄糖協同轉運蛋白1的抑制劑
HK1244183A1 (zh)	2018-08-03	Ivacaftor的氘化衍生物
PL2742051T3 (pl)	2017-06-30	Amorficzna postać soli sodowej dolutegrawiru
SMT201600072B (it)	2016-04-29	Sale sodico di 6-fluoro-3-idrossi-2-pirazina carbossammide
EP2681200A4 (en)	2015-05-27	INHIBITORS OF BENZIMIDAZOLE TYPE OF SODIUM CHANNEL
EP2686330A4 (en)	2014-11-12	SYNTHESIS OF NEW FUCOSE-CONTAINING CARBOHYDRATE DERIVATIVES
HUE047354T2 (hu)	2020-04-28	Ivacaftor deuterizált származékai
EP2916656A4 (en)	2016-09-14	INHIBITORS OF MALT1 WITH SMALL MOLECULES
HK1201273A1 (zh)	2015-08-28	-β- -脫氧- -氟- -硫代-β- -阿拉伯呋喃糖基胞嘧啶的鹽
EP2661179A4 (en)	2014-12-24	COMPOSITION WITH REDUCED SODIUM CONTENT
HK1210776A1 (en)	2016-05-06	Substituted sodium 1h-pyrazol-5-olate 1h--5-
EP3003320A4 (en)	2016-10-19	NEW POLYMORPHE OF REGADENOSON
EP2688426A4 (en)	2014-08-27	SALT COMPOSITION WITH REDUCED SODIUM CONTENT
EP2914253A4 (en)	2016-04-27	CYCLIC SULFONAMIDE-CONTAINING DERIVATIVES AS INHIBITORS OF THE HEDGEHOG SIGNALING PATH
AU2012902375A0 (en)	2012-06-21	Low sodium salt
EP2716013A4 (en)	2015-08-19	CIRCUITRY FOR MAINTAINING CORRELATION BETWEEN ADDRESS SETS
TH125283B (th)	2013-07-05	ผลิตภัณฑ์สวมใส่